| Literature DB >> 25602448 |
Ehab Farag1, Kamal Maheshwari, Joseph Morgan, Wael Ali Sakr Esa, D John Doyle.
Abstract
The renin angiotensin system (RAS) is thought to be the body's main vasoconstrictor system, with physiological effects mediated via the interaction of angiotensin II with angiotensin I receptors (the "classic" RAS model). However, since the discovery of the heptapeptide angiotensin 1-7 and the development of the concept of the "alternate" RAS system, with its ability to reduce arterial blood pressure, our understanding of this physiologic system has changed dramatically. In this review, we focus on the newly discovered functions of the RAS, particularly the potential clinical significance of these developments, especially in the realm of new pharmacologic interventions for treating cardiovascular disease.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25602448 DOI: 10.1213/ANE.0000000000000528
Source DB: PubMed Journal: Anesth Analg ISSN: 0003-2999 Impact factor: 5.108